CYTENA Signs USD 10 Million Deal to Distribute Single Cell Isolators in China to Accelerate Development of Next Generation Therapies

The 2-year deal with Applitech Pharmaceutical Equipment Technology further strengthens BICO’s close collaboration and will see nearly 100 of CYTENA’s latest portfolio of cell isolators including the UP.SIGHT to be distributed to the massive Chinese life science market

Today CYTENA, a BICO company, announced it has signed a 2-year deal with Applitech Pharmaceutical Equipment Technology to distribute its single cell isolators in China. The deal worth more than USD 10 million will see nearly 100 of the company’s single cell isolators including the UP.SIGHT devices be distributed in the world’s second largest life science market. The deal advances BICO’s bio convergence agenda by accelerating the development of next generation treatments including gene therapies, biosimilars, and monoclonal antibodies.

“The life science market in China is one of the most impressive in the world and we’re thrilled with this deal to be able to help researchers there accelerate their life saving work,” said Erik Gatenholm, CEO and co-founder of BICO. “Applitech is the perfect partner to help us grow our market share at this pivotal time.”

As one of the leading life science markets, China is a key country for BICO as it advances the global bio convergence revolution. Worth more than $210 billion in 2020, the Chinese life science market is growing at an incredible 10% year-over-year, and this deal will help CYTENA and BICO grow its share of that market. The deal includes an initial $10 million contract for nearly 100 devices from BICO’s CYTENA, with opportunity for additional sales later on. The deal aligns with a key part of BICO’s Next Generation Core Industrial Ecosystems, namely Next Generation Cell Line Development.

“CYTENA’s single cell isolators have helped researchers across the world advance cell line development research,” explained Jonas Schöndube, BICO’s Business Area Director for Biosciences. “We’re thrilled to expand our footprint in China and help drive innovation across gene therapies, biosimilars, and monoclonal antibodies.”

For more information or to find out more about CYTENA’s single cell isolation technology, please visit www.cytena.com

For further information, please contact:
Isabelle Ljunggren, Head of Communications
Phone (Sweden): +46 70 830 0890
Email: [email protected]

BICO Press office
Phone (US):
Riley Munks, PR Manager: (650) 863-6699
Alyssa D’Orazio, PR Manager: (617) 634-9601
Email: [email protected]

This information was submitted for publication, through the agency of the contact persons set out above, on December 7, 2021, at 4:40pm (CET).

About BICO

Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people’s health and lives for the better.

The company has a focus on developing technologies that will advance Health 4.0 Next Generation Core Industry Ecosystems that enable tissue engineering, diagnostics, multiomics, and cell line development. BICO’s technologies enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.

The Group’s instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com

About CYTENA

CYTENA is a leading provider of high-precision instruments for isolating, dispensing, imaging, analyzing and handling biological cells, and continues to build on the success of the single-cell dispensing technology the company patented as a spin-off from the University of Freiburg, Germany, in 2014. Today, as part of BICO, the world’s leading bioconvergence company, CYTENA’s award-winning devices are still manufactured in Germany and used at prestigious academic and pharmaceutical labs around the world to automate workflows in numerous application areas, including stable cell line development, single-cell omics, high-throughput screening and drug discovery.

CYTENA’s breakthrough innovations for the lab combine advanced automation, state-of-the-art software engineering and the latest insights in cell biology to maximize efficiencies in the life sciences and create the future of health. Learn more at www.cytena.com

Applitech_ENG_final

More News